Skip to main content
SpringerLink
Log in

Testosterone in Transgender Population

  • Chapter
  • First Online:
Controversies in Testosterone Deficiency

Abstract

Gender affirming hormonal treatment (GAHT) in transgender men consists of testosterone treatment in different formulations. The main goal of testosterone treatment is to achieve cisgender male serum testosterone levels in order to induce virilization. The desired effects include increased facial and body hair, deepening of the voice, cessation of menses, fat redistribution and increased lean mass and strength, as well as improvement of psychological well-being. However, testosterone treatment may induce potential undesired effects and risks, such as acne, androgenetic alopecia, increase in systolic blood pressure, haematocrit and changes in lipid profile. GAHT in transgender men is considered safe on the short term and middle term, although several aspects, such as long-term cardiovascular and oncological safety, need to be adequately assessed in the future through long-term prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organisation. International classification of diseases 11th revision. Geneva: World Health Organisation; 2018. Available at: https://icd.who.int/. Accessed 27 Aug 2018.

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Arlington: American Psychiatric Publishers; 2013.

    Book  Google Scholar 

  3. Arcelus J, De Vries ALC, Fisher AD, Nieder TO, Özer M, Motmans J. European Society for Sexual Medicine Position Statement “Assessment and hormonal management in adolescent and adult trans people, with attention for sexual function and satisfaction”. J Sex Med. 2020;pii:S1743-6095(20)30045-X. https://doi.org/10.1016/j.jsxm.2020.01.012. [Epub ahead of print].

    Article  CAS  Google Scholar 

  4. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13:165–232.

    Article  Google Scholar 

  5. Heylens G, Verroken C, De Cock S, et al. Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J Sex Med. 2014;11(1):119–26.

    Article  PubMed  Google Scholar 

  6. Fisher AD, Castellini G, Bandini E, et al. Cross-sex hormonal treatment and body uneasiness in individuals with gender dysphoria. J Sex Med. 2014;11(3):709–19.

    Article  CAS  PubMed  Google Scholar 

  7. Fisher AD, Castellini G, Ristori J, et al. Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. J Clin Endocrinol Metab. 2016;101(11):4260–9.

    Article  CAS  PubMed  Google Scholar 

  8. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med. 2012;9(2):531–41.

    Article  PubMed  Google Scholar 

  9. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903.

    Article  PubMed  Google Scholar 

  10. Cocchetti C, Ristori J, Romani A, et al. Hormonal treatment strategies tailored to non-binary transgender individuals. J Clin Med. 2020;9(6):1609.

    Article  CAS  PubMed Central  Google Scholar 

  11. Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology. 2018;6:446–54.

    Article  CAS  PubMed  Google Scholar 

  12. Pelusi C, Costantino A, Martelli V, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11:3002–11.

    Article  PubMed  Google Scholar 

  13. Evans S, Neave N, Wakelin D, et al. The relationship between testosterone and vocal frequencies in human males. Physiol Behav. 2008;93(4–5):783–8.

    Article  CAS  PubMed  Google Scholar 

  14. Bultynck C, Pas C, Defreyne J, et al. Self-perception of voice in transgender persons during cross-sex hormone therapy. Laryngoscope. 2017;127(12):2796–804.

    Article  CAS  PubMed  Google Scholar 

  15. Abitbol J, Abitbol P, Abitbol B. Sex hormones and the female voice. J Voice. 1999;13(3):424–46.

    Article  CAS  PubMed  Google Scholar 

  16. Cosyns M, Borsel J, Wierckx K, et al. Voice in female-to-male transsexual persons after long-term androgen therapy. Laryngoscope. 2014;124(6):1409–14.

    Article  CAS  PubMed  Google Scholar 

  17. Watt SO, Tskhay KO, Rule NO. Masculine voices predict well-being in female-tomale transgender individuals. Arch Sex Behav. 2017;47:963–72.

    Article  PubMed  Google Scholar 

  18. Giltay EJ, Gooren LJG. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab. 2000;85(8):2913–21.

    Article  CAS  PubMed  Google Scholar 

  19. Wierckx K, Van de Peer F, Verhaeghe E, et al. Short-and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014;11(1):222–9.

    Article  CAS  PubMed  Google Scholar 

  20. Mueller A, Kiesewetter F, Binder H, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab. 2007;92(9):3470–5.

    Article  CAS  PubMed  Google Scholar 

  21. Nakamura A, Watanabe M, Sugimoto M, Sako T, Mahmood S, Kaku H, Nasu Y, Ishii K, Nagai A, Kumon H. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J. 2013;60(3):275–81. Epub 2012 Oct 27.

    Article  CAS  PubMed  Google Scholar 

  22. Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11:1999–2011.

    Article  CAS  PubMed  Google Scholar 

  23. Allan CA, Forbes EA, Strauss BJG, et al. Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res. 2008;20(4):396–401.

    Article  CAS  PubMed  Google Scholar 

  24. Costantino A, Cerpolini S, Alvisi S, et al. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther. 2013;39(4):321–35.

    Article  PubMed  Google Scholar 

  25. Somboonporn W, Davis S, Seif MW, et al. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev. 2005;(4):CD004509.

    Google Scholar 

  26. Wierckx K, Elaut E, Van Caenegem E, et al. Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration. Eur J Endocrinol. 2011;165(2):331–7.

    Article  CAS  PubMed  Google Scholar 

  27. Ristori J, Cocchetti C, Castellini G, Pierdominici M, Cipriani A, Testi D, Gavazzi G, Mazzoli F, Mosconi M, Meriggiola MC, Cassioli E, Vignozzi L, Ricca V, Maggi M, Fisher AD. Hormonal treatment effect on sexual distress in transgender persons: 2-year follow-up data. J Sex Med. 2020;17(1):142–51.

    Article  CAS  PubMed  Google Scholar 

  28. Berra M, Armillotta F, D’Emidio L, et al. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl. 2006;8:725–9.

    Article  CAS  PubMed  Google Scholar 

  29. Colizzi M, Costa R, Scaramuzzi F, et al. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study. J Psychosom Res. 2015;78:399–406.

    Article  PubMed  Google Scholar 

  30. Mueller A, Haeberle L, Zollver H, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med. 2010;7:3190–8.

    Article  CAS  PubMed  Google Scholar 

  31. Quiros C, Patrascioiu I, Mora M, et al. Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia. Endocrinol Nutr. 2015;62:210–6.

    Article  PubMed  Google Scholar 

  32. Van Caenegem E, Wierckx K, Taes Y, et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol. 2015;172:163–71.

    Article  PubMed  CAS  Google Scholar 

  33. Deplewski D, Rosenfiled R. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363–92.

    Article  CAS  PubMed  Google Scholar 

  34. Ebling FJ, Skinner J. The measurements of sebum production in rats treated with T and oestradiol. Br J Dermatol. 1967;79:386–93.

    Article  CAS  PubMed  Google Scholar 

  35. Baldassarre M, Giannone FA, Foschini MP, et al. Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor-α and -β expression of young women. Int J Impot Res. 2013;25:172–7.

    Article  CAS  PubMed  Google Scholar 

  36. Schlatterer K, Von Werder K, Stalla GK. Multistep treatment concept of transsexual patients. Exp Clin Endocrinol Diabetes. 1996;104(06):413–9.

    Article  CAS  PubMed  Google Scholar 

  37. Grynberg M, Fanchin R, Dubost G, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online. 2010;20:553–8.

    Article  CAS  PubMed  Google Scholar 

  38. Perrone AM, Cerpolini S, Maria Salfi NC, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009;6:3193–200.

    Article  CAS  PubMed  Google Scholar 

  39. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;72:1–10.

    Article  CAS  Google Scholar 

  41. Olson-Kennedy J, Okonta V, Clark LF, et al. Physiologic response to gender affirming hormones among transgender youth. J Adolesc Health. 2017;62(4):397–401.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Fernandez JD, Tannock LR. Metabolic effects of hormone therapy in transgender patients. Endocr Pract. 2015;22(4):383–8.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas. 2018;107:92–6.

    Article  CAS  PubMed  Google Scholar 

  44. Cupisti S, Giltay EJ, Gooren LJ, et al. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril. 2010;94(7):2647–53.

    Article  CAS  PubMed  Google Scholar 

  45. Chandra P, Basra SS, Chen TC, et al. Alterations in lipids and adipocyte hormones in female-to-male transsexuals. Int J Endocrinol. 2010;2010 [pii:945053].

    Google Scholar 

  46. Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015;125(3):605–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wultsch A, Kaufmann U, Ott J, et al. Profound changes in sex hormone levels during cross-sex hormone therapy of transsexuals do not alter serum cholesterol acceptor capacity. J Sex Med. 2015;12(6):1436–9.

    Article  CAS  PubMed  Google Scholar 

  48. Elbers JMH, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003;58(5):562–71.

    Article  CAS  Google Scholar 

  49. Jacobeit JW, Gooren LJ, Schulte HM. Endocrinology: long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med. 2007;4(5):1479–84.

    Article  CAS  PubMed  Google Scholar 

  50. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol. 2009;161(5):795–8.

    Article  CAS  PubMed  Google Scholar 

  51. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2017;102(11):3914–23.

    Article  PubMed  Google Scholar 

  52. Giltay EJ, Toorians AWFT, Sarabjitsingh AR, et al. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-tomale transsexuals. J Endocrinol. 2004;180(1):107–12.

    Article  CAS  PubMed  Google Scholar 

  53. Polderman KH, Gooren LJ, Asscheman H, et al. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab. 1994;79(1):265–71.

    CAS  PubMed  Google Scholar 

  54. Auer MK, Ebert T, Pietzner M, Defreyne J, Fuss J, Stalla GK, T’Sjoen G. Effects of sex hormone treatment on the metabolic syndrome in transgender individuals: focus on metabolic cytokines. J Clin Endocrinol Metab. 2018;103(2):790–802.

    Article  PubMed  Google Scholar 

  55. Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88:5723–9.

    Article  CAS  PubMed  Google Scholar 

  56. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9:2641–51.

    Article  CAS  PubMed  Google Scholar 

  57. Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93:1267–72.

    Article  PubMed  Google Scholar 

  58. Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169:471–8.

    Article  CAS  PubMed  Google Scholar 

  59. Bird D, Vowles K, Anthony PP. Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: report of a case successfully treated by emergency right hepatic lobectomy. Br J Surg. 1979;66(3):212–3.

    Article  CAS  PubMed  Google Scholar 

  60. Westaby D, Paradinas FJ, Ogle SJ, et al. Liver damage from long-term methyltestosterone. Lancet. 1977;310(8032):261–3.

    Article  Google Scholar 

  61. Sorelle JA, Jiao R, Gao E, Veazey J, Frame I, Quinn AM, Day P, Pagels P, Gimpel N, Patel K. Impact of hormone therapy on laboratory values in transgender patients. Clin Chem. 2019;65(1):170–9.

    Article  CAS  PubMed  Google Scholar 

  62. Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Effect of sex steroids on the bone health of transgender individuals: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2017;102(11):3904–13.

    Article  PubMed  Google Scholar 

  63. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab. 2012;97(7):2503–11.

    Article  PubMed  CAS  Google Scholar 

  64. Miyajima T, Kim YT, Oda H. A study of changes in bone metabolism in cases of gender identity disorder. J Bone Miner Metab. 2012;30(4):468–73.

    Article  CAS  PubMed  Google Scholar 

  65. Goh HHV, Ratnam SS. Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Maturitas. 1997;26(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  66. Van Kesteren P, Lips P, Gooren LJG, et al. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf). 1998;48(3):347–54.

    Article  Google Scholar 

  67. Slagter MH, Gooren LJ, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem. 2006;54:905–10.

    Article  CAS  PubMed  Google Scholar 

  68. Stone JP, Hartley RL, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. Part 2: female to male. Eur J Surg Oncol. 2018;44:1463–8.

    Article  PubMed  Google Scholar 

  69. Nikolic DV, Djordjevic ML, Granic M, et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol. 2012;10(1):280.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Burcombe RJ, Makris A, Pittam M, et al. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast. 2003;12(4):290–3.

    Article  CAS  PubMed  Google Scholar 

  71. Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer. 2011;11(6):417–9.

    Article  PubMed  Google Scholar 

  72. Gooren L, Bowers M, Lips P, et al. Five new cases of breast cancer in transsexual persons. Andrologia. 2015;47(10):1202–5.

    Article  CAS  PubMed  Google Scholar 

  73. Van Renterghem SMJ, Van Dorpe J, Monstrey SJ, et al. Routine histopathological examination after female-to-male gender-confirming mastectomy. Br J Surg. 2018;105(7):885–92.

    Article  PubMed  Google Scholar 

  74. Urban RR, Teng NNH, Kapp DS. Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance. Am J Obstet Gynecol. 2011;204(5):e9–12.

    Article  PubMed  Google Scholar 

  75. Dria’k D, Samudovsky M. Could a man be affected with carcinoma of cervix?- The first case of cervical carcinoma in trans-sexual person (FtM)-case report. Acta Medica (Hradec Kralove). 2005;48(1):53.

    Article  Google Scholar 

  76. Taylor ET, Bryson MK. Cancer’s margins: trans* and gender nonconforming people’s access to knowledge, experiences of cancer health, and decision-making. LGBT Health. 2016;3(1):79–89.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Brown B, Poteat T, Marg L, Galea JT. Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: neglected populations at high risk. LGBT Health. 2017;4(5):315–9.

    Article  PubMed  Google Scholar 

  78. Futterweit W. Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav. 1998;27(2):209–26.

    Article  CAS  PubMed  Google Scholar 

  79. Dizon DS, Tejada-Berges T, Koelliker S, et al. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest. 2006;62(4):226–8.

    Article  PubMed  Google Scholar 

  80. Hage JJ, Dekker J, Karim RB, et al. Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol. 2000;76(3):413–5.

    Article  CAS  PubMed  Google Scholar 

  81. Clements-Nolle K, Marx R, Katz M. Attempted suicide among transgender persons: the influence of gender-based discrimination and victimization. J Homosex. 2006;51(3):53–69.

    Article  PubMed  Google Scholar 

  82. Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health. 2013;103(5):943–51.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Budge SL, Adelson JL, Howard KAS. Anxiety and depression in transgender individuals: the roles of transition status, loss, social support, and coping. J Consult Clin Psychol. 2013;81(3):545.

    Article  PubMed  Google Scholar 

  84. Witcomb GL, Bouman WP, Claes L, et al. Levels of depression in transgender people and its predictors: results of a large matched control study with transgender people accessing clinical services. J Affect Disord. 2018;235:308–15.

    Article  PubMed  Google Scholar 

  85. Defreyne J, Kreukels B, T’Sjoen G, Staphorsius A, Den Heijer M, Heylens G, Elaut E. No correlation between serum testosterone levels and state-level anger intensity in transgender people: results from the European Network for the Investigation of Gender Incongruence. Horm Behav. 2019;110:29–39.

    Article  CAS  PubMed  Google Scholar 

  86. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164:635–42.

    Article  CAS  PubMed  Google Scholar 

  87. Dhejne C, Lichtenstein P, Boman M, Johansson AL, Langstrom N, Landen M. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLoS One. 2011;6:e16885.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf). 2010;72(2):214–31.

    Article  Google Scholar 

  89. Defreyne J, Motmans J, T’Sjoen G. Healthcare costs and quality of life outcomes following gender affirming surgery in trans men: a review. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):543–56.

    Article  PubMed  Google Scholar 

  90. Kuhn A, Bodmer C, Stadlmayr W, et al. Quality of life 15 years after sex reassignment surgery for transsexualism. Fertil Steril. 2009;92(5):1685–1689.e3.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Andrology, Women’s Endocrinology and Gender Incongruence Unit, Careggi University Hospital, Florence, Italy

    Carlotta Cocchetti & Alessandra Daphne Fisher

Authors
  1. Carlotta Cocchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Daphne Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandra Daphne Fisher .

Editor information

Editors and Affiliations

  1. Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    John P. Mulhall

  2. Endocrinology, University of Firenze, Firenze, Firenze, Italy

    Mario Maggi

  3. Male Fertility and Peyronie’s Clinic, Orem, UT, USA

    Landon Trost

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cocchetti, C., Fisher, A.D. (2021). Testosterone in Transgender Population. In: Mulhall, J.P., Maggi, M., Trost, L. (eds) Controversies in Testosterone Deficiency . Springer, Cham. https://doi.org/10.1007/978-3-030-77111-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-77111-9_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-77110-2

  • Online ISBN: 978-3-030-77111-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation